Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00187564

Enrollment

Registered

2005-09-16

Start date

2004-08-31

Completion date

2005-10-31

Last updated

2008-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Keywords

Diabetes Mellitus, Type 1, lipoic acid, oxidative stress

Brief summary

The long-term effects of high blood sugar include blindness, kidney failure, and nerve damage that can ultimately cause loss of limbs. Research has shown that high blood sugar increases the amount of reactive oxygen species (ROS) produced in diabetics, and that the increase in ROS causes damage to eyes, kidneys, and nerves by a process called oxidative stress. We postulate that alpha-lipoic acid, a potent anti-oxidant, can stop ROS from forming, thereby preventing long-term complications in diabetes. In this pilot study, we will be giving 30 teenagers with type 1 diabetes (T1D) controlled-release alpha-lipoic acid for 3 months, and comparing the amount of oxidative stress before and after treatment. Ten teenagers with T1D will receive placebo instead of alpha-lipoic acid and undergo the same research protocol to aid in validation of outcome measures.

Interventions

DRUGcontrolled-release oral alpha-lipoic acid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

8 Years to 21 Years

Healthy volunteers

Inclusion criteria

1. Subjects must be pubertal (defined as Tanner stage II or greater), or post-pubertal, with an upper age limit of 21 years. 2. Subjects must have diabetes by 1997 ADA criteria: 1. fasting plasma glucose \>= 126 mg/dL, or 2. 2 hour postprandial glucose \>= 200 mg/dL 3. Subjects must have history of least one auto-antibody associated with T1D, either glutamic acid decarboxylase (GADA) or islet cell autoantigen 512 (ICA512), or history of diabetic ketoacidosis.

Exclusion criteria

1\. Subjects must not have history of eye, kidney or nerve damage 2. Subjects must not be deemed unable or unlikely to comply with the protocol. Children who are unable to swallow pills, or are unwilling to take pills twice daily will be excluded from the study. \-

Design outcomes

Primary

Measure	Time frame
1. protein carbonyl (measurement of oxidized protein)	—
2. Thiobarbituric Acid Reactive Substances (TBARS) (measurement of oxidized lipid)	—
3. 8-Oxo-dG/8-Oxo-dA (measurement of oxidized DNA)	—
4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status)	—

Secondary

Measure	Time frame
1. Hb A1c	—
2. Urine albumin/creatinine ratio	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026